MIR-127 Treatment Renal Fibrosis Patent, Apr 15, 2026
Summary
The European Patent Office published application EP3500270A1 for MIR-127 therapeutic agents for use in treating renal fibrosis. The patent application, filed by Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal, covers miRNA-based compositions classified under A61K 31/7105 and C12N 15/113. Protection extends to 38 designated EU and EEA contracting states including Germany, France, the United Kingdom, Spain, Italy, and the Netherlands.
About this source
GovPing monitors EPO Patent Bulletin - Pharma (A61K) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 58 changes logged to date.
What changed
The European Patent Office published patent application EP3500270A1 for MIR-127 therapeutic agents used in the treatment of renal fibrosis, filed by Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal. The application covers miRNA-based pharmaceutical compositions with IPC classifications A61K 31/7105 and C12N 15/113.
Parties interested in the therapeutic use of MIR-127 for renal fibrosis should review freedom-to-operate positions in designated contracting states. Generic or biosimilar developers targeting the same miRNA mechanism for fibrotic kidney disease may need to consider licensing negotiations or design-around strategies prior to commercialisation in EU/EEA markets.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MIR-127 AGENTS FOR USE IN THE TREATMENT OF RENAL FIBROSIS
Publication EP3500270A1 Kind: A1 Apr 15, 2026
Applicants
Fundación Para La Investigación Biomédica Del
Hospital Universitario Ramón Y Cajal
Inventors
GARCÍA BERMEJO, Laura, CONDE MORENO, Elisa, GIMENEZ MOYANO, Sara, MARTÍN GÓMEZ, Laura
IPC Classifications
A61K 31/7105 20060101AFI20180223BHEP C12N 15/113 20100101ALI20180223BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.